# OnCo record cholangiocarcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cholangiocarcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cholangiocarcinoma" ;
  schema:name "Biliary tract cancer (cholangiocarcinoma)"@en ;
  schema:alternateName "Bile Duct Cancer"@en ;
  schema:description "Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."@en ;
  schema:url <https://onco.cc/cancers/cholangiocarcinoma/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cholangiocarcinoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q124292> ;
  schema:citation <https://en.wikipedia.org/wiki/Cholangiocarcinoma> ;
  onco:tag "gi", "spike" ;
  onco:related <https://onco.cc/pairings/gemcis-plus-io-btc/>, <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/ampullary/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/technologies/liver-transplant-oncology/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/technologies/rna-seq/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/sbrt/> ;
  onco:targets <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/idh/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/cldn18-2/> ;
  onco:drugs <https://onco.cc/drugs/oncomine-dx-target-test/> ;
  onco:companies <https://onco.cc/companies/shenzhen-ionova-life-sciences/>, <https://onco.cc/companies/hangzhou-hanx-biopharmaceuticals/>, <https://onco.cc/companies/tiumbio/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/incyte/>, <https://onco.cc/companies/taiho/>, <https://onco.cc/companies/servier/>, <https://onco.cc/companies/jazz/>, <https://onco.cc/companies/zymeworks/>, <https://onco.cc/companies/merus/>, <https://onco.cc/companies/transthera/> ;
  onco:institutions <https://onco.cc/institutions/mayo-clinic/>, <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/cruk/>, <https://onco.cc/institutions/royal-marsden/>, <https://onco.cc/institutions/asan-medical-center/> ;
  onco:terms <https://onco.cc/terms/biliary-anatomy-subtypes/>, <https://onco.cc/terms/fgfr2-fusion/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/tumour-agnostic/> ;
  onco:trials <https://onco.cc/trials/nct07229625/>, <https://onco.cc/trials/nct05065957/>, <https://onco.cc/trials/nct06622057/>, <https://onco.cc/trials/nct05987358/>, <https://onco.cc/trials/nct04353375/>, <https://onco.cc/trials/companion-002/>, <https://onco.cc/trials/nct07265674/>, <https://onco.cc/trials/nct07710885/>, <https://onco.cc/trials/nct05771480/>, <https://onco.cc/trials/nct06467357/>, <https://onco.cc/trials/nct05876754/>, <https://onco.cc/trials/nct06109779/>, <https://onco.cc/trials/nct07582315/>, <https://onco.cc/trials/nct07606599/>, <https://onco.cc/trials/nct03478488/>, <https://onco.cc/trials/nct05948475/>, <https://onco.cc/trials/nct07221253/>, <https://onco.cc/trials/nct06591520/>, <https://onco.cc/trials/abc-06/>, <https://onco.cc/trials/fight-302/> ;
  onco:pipeline <https://onco.cc/drugs/zenocutuzumab/>, <https://onco.cc/drugs/shr-8068/>, <https://onco.cc/drugs/tqb2102/>, <https://onco.cc/drugs/d07001/>, <https://onco.cc/drugs/tqb3454/>, <https://onco.cc/drugs/hmpl-453/>, <https://onco.cc/drugs/tovecimig/>, <https://onco.cc/drugs/xnw27011/>, <https://onco.cc/drugs/azd4360/>, <https://onco.cc/drugs/cgt4859/>, <https://onco.cc/drugs/spevatamig/>, <https://onco.cc/drugs/vb15010/>, <https://onco.cc/trials/herizon-btc-302/>, <https://onco.cc/trials/first-308/>, <https://onco.cc/drugs/tinengotinib/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/ideas/idea-btc-ctdna-fgfr-resistance/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/liver-transplant-oncology/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/technologies/fapi-pet/>, <https://onco.cc/drugs/cmg901/> ;
  onco:standardOfCare <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/zenocutuzumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/rna-seq/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/trials/bilcap/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/liver-transplant-oncology/>, <https://onco.cc/trials/topaz-1/>, <https://onco.cc/trials/keynote-966/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/herizon-btc-302/>, <https://onco.cc/drugs/pemigatinib/>, <https://onco.cc/drugs/futibatinib/>, <https://onco.cc/drugs/tinengotinib/>, <https://onco.cc/trials/fight-202/>, <https://onco.cc/trials/foenix-cca2/>, <https://onco.cc/trials/first-308/>, <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/trials/claridhy/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/zenocutuzumab/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/trials/naliricc/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/technologies/sbrt/> .
